- Home
- IMMX vs DHAI Comparison
IMMX vs DHAI Comparison
Compare IMMX & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- DHAI
- Stock Information
- Founded
- IMMX 2014
- DHAI 2007
- Country
- IMMX United States
- DHAI United States
- Employees
- IMMX N/A
- DHAI N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- DHAI
- Sector
- IMMX Health Care
- DHAI
- Exchange
- IMMX Nasdaq
- DHAI NYSE
- Market Cap
- IMMX 50.1M
- DHAI 49.1M
- IPO Year
- IMMX 2021
- DHAI N/A
- Fundamental
- Price
- IMMX $1.61
- DHAI $0.22
- Analyst Decision
- IMMX Strong Buy
- DHAI
- Analyst Count
- IMMX 1
- DHAI 0
- Target Price
- IMMX $7.00
- DHAI N/A
- AVG Volume (30 Days)
- IMMX 48.0K
- DHAI 597.4K
- Earning Date
- IMMX 05-08-2025
- DHAI 02-14-2025
- Dividend Yield
- IMMX N/A
- DHAI N/A
- EPS Growth
- IMMX N/A
- DHAI N/A
- EPS
- IMMX N/A
- DHAI N/A
- Revenue
- IMMX N/A
- DHAI $69,573,000.00
- Revenue This Year
- IMMX N/A
- DHAI N/A
- Revenue Next Year
- IMMX N/A
- DHAI N/A
- P/E Ratio
- IMMX N/A
- DHAI N/A
- Revenue Growth
- IMMX N/A
- DHAI 5.40
- 52 Week Low
- IMMX $1.26
- DHAI $0.22
- 52 Week High
- IMMX $3.13
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- IMMX 40.16
- DHAI 28.55
- Support Level
- IMMX $1.36
- DHAI $0.24
- Resistance Level
- IMMX $1.90
- DHAI $0.28
- Average True Range (ATR)
- IMMX 0.16
- DHAI 0.04
- MACD
- IMMX -0.01
- DHAI 0.01
- Stochastic Oscillator
- IMMX 35.77
- DHAI 2.28
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.